Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
CG
Compugen Ltd
CGEN
Mkt Cap
$185.2M
Volume
166.88K
Next Earnings
November 9th
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
CG
CGEN
CG
Compugen Ltd
CGEN
News
·
Longboard (LBPH) Up 14% as Epilepsy Drug Gets Breakthrough Tag
Mkt Cap
$185.7M
Volume
166.88K
Next Earnings
November 9th
Chart
Financials
Earnings
News
About
Insider
Filings
Longboard (LBPH) Up 14% as Epilepsy Drug Gets Breakthrough Tag
Longboard (LBPH) gains 14% as the FDA grants the Breakthrough Therapy designation to its investigational epilepsy treatment candidate, bexicaserin, for patients aged two years or older.
Zacks Investment Research · Jul 2, 2024
FDA Rejects Rocket's (RCKT) Gene Therapy BLA for Rare Disease
Per the FDA, Rocket (RCKT) needs to submit additional manufacturing information on Kresladi gene therapy to secure approval for severe leukocyte adhesion deficiency-I (LAD-I), a rare genetic disorder.
Zacks Investment Research · Jul 1, 2024
Apellis (APLS) Falls on Second Negative CHMP Opinion for GA Drug
Apellis (APLS) declines as CHMP issues a second negative opinion for the approval of intravitreal pegcetacoplan to treat GA in the EU. The company plans to seek re-examination of the same.
Zacks Investment Research · Jul 1, 2024
PTC Therapeutics (PTCT) Down on Negative CHMP Opinion on DMD Drug
PTC Therapeutics (PTCT) falls as the EC's advisory committee adopts a negative opinion regarding the renewal of the conditional marketing approval of Translarna to treat nmDMD in the EU.
Zacks Investment Research · Jul 1, 2024
Cogent (COGT) Up on SUMMIT Study Update Post Positive FDA Meeting
Cogent (COGT) announces a positive FDA meeting and alignment on MS2D2, a novel patient-reported outcome measure for the SUMMIT study. The company's shares rise on the news.
Zacks Investment Research · Jun 28, 2024
Merck's (MRK) New Pneumococcal Jab Capvaxive Gets CDC Panel Vote
Merck's (MRK) vaccine, Capvaxive, gets unanimous recommendation by a CDC committee for adults aged 65 years and older for pneumococcal vaccination and those with certain other underlying conditions.
Zacks Investment Research · Jun 28, 2024
Novo Nordisk's (NVO) Hypertension Drug Study Fails to Meet Goal
Novo Nordisk (NVO) declines as a late-stage study of its uncontrolled hypertension and advanced chronic kidney disease candidate, ocedurenone, fails to achieve the primary goal.
Zacks Investment Research · Jun 27, 2024
CASI Pharmaceuticals (CASI) Up on Buyout Offer for China Business
CASI Pharmaceuticals (CASI) gets a proposal letter from its chairman for acquiring its business operations in China. Its shares rise on the news.
Zacks Investment Research · Jun 27, 2024
Bayer's (BAYRY) AskBio Advances Parkinson Disease Study
Bayer's (BAYRY) wholly owned and independently operating subsidiary AskBio started recruitment in the phase II study for Parkinson's disease.
Zacks Investment Research · Jun 26, 2024
ImmunityBio (IBRX) Gains 17% in the Past Week: Here's Why
ImmunityBio (IBRX) rises 17% in the past week as it announces insurance coverage as well as the treatment of the first patients with its newly approved bladder cancer immunotherapy, Anktiva.
Zacks Investment Research · Jun 26, 2024
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
CG
CGEN
Compugen Ltd
Buy
Sell
Market
Limit
Soon
CGEN
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any CGEN yet.
Related Tickers
Earnings